Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017153939) PHARMACEUTICAL COMPOSITION COMPRISING CANAGLIFLOZIN, PROCESS OF PREPARATION AND USE THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/153939 International Application No.: PCT/IB2017/051377
Publication Date: 14.09.2017 International Filing Date: 09.03.2017
IPC:
A61K 9/20 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
20
Pills, lozenges or tablets
Applicants:
BARIK, Satyabrata [IN/IN]; IN
CHOKKASANDRA JAYARAMAREDDY, Venugopala [IN/IN]; IN
MEENAKSHISUNDERAM, Sivakumaran [IN/IN]; IN
AUROBINDO PHARMA LIMITED [IN/IN]; Aurobindo Pharma Limited, The Water Mark Building, Plot No.11, Survey No.9, Kondapur, Hitech City, Hyderabad, Pin - 500 084, Telangana, Hyderabad 500 084, IN
Inventors:
BARIK, Satyabrata; IN
CHOKKASANDRA JAYARAMAREDDY, Venugopala; IN
MEENAKSHISUNDERAM, Sivakumaran; IN
Common
Representative:
AUROBINDO PHARMA LIMITED; IN
Priority Data:
20164100834910.03.2016IN
Title (EN) PHARMACEUTICAL COMPOSITION COMPRISING CANAGLIFLOZIN, PROCESS OF PREPARATION AND USE THEREOF
(FR) COMPOSITION PHARMACEUTIQUE COMPRENANT DE LA CANAGLIFLOZINE, PROCÉDÉ DE PRÉPARATION ET UTILISATION DE CELLE-CI
Abstract:
(EN) The present invention relates to a binder free pharmaceutical composition comprising canagliflozin or a prodrug or a pharmaceutically acceptable salt thereof, and one or more 5 pharmaceutically acceptable excipients, wherein the said composition is devoid of canagliflozin hemihydrate, and having acceptable chemical stability, polymorphic stability & comparative dissolution and bioequivalence profile to that of INVOKANA® tablets.
(FR) La présente invention concerne une composition pharmaceutique sans liant comprenant de la canagliflozine ou un promédicament ou sel pharmaceutiquement acceptable de celle-ci, et un ou plusieurs excipients pharmaceutiquement acceptables, où ladite composition est exempte de canaglifozine hémihydratée, et présente un profil acceptable de stabilité chimique, de stabilité polymorphique et de bioéquivalence et dissolution comparative, par rapport à celui des comprimés INVOKANA®.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)